Amyotrophic Lateral Sclerosis Market Research Report - Forecast to 2027

Amyotrophic Lateral Sclerosis Market Research Report: By Type (Familial ALS), by Treatment (Medication, Physical Therapy, Speech Therapy), by Diagnosis (Laboratory Tests, Imaging Tests), End-User (Hospitals, Specialty Centers)- Forecast till 2027

ID: MRFR/Pharma/4366-CR | | Region: Global | 115 pages

Amyotrophic Lateral Sclerosis Market Speak to Analyst Request a Free Sample

Amyotrophic Lateral Sclerosis Market Overview

A group of rare neurological disorders includes amyotrophic lateral sclerosis (ALS). The neurons in the brain and spinal cord are severely affected by this neurodegenerative disease. These disorders affect the voluntary muscles in the body and can also be called motor neuron disorders. An ALS patient may experience muscle twitching and shrinking muscles. The market for amyotrophic lateral sclerosis is expected to grow due to factors such as an increase in the incidence rate and awareness of the disease, as well as a rise in the geriatric population.


Over the forecast period (2018-2023), the Global amyotrophic lateral sclerosis market will exceed USD 841.6 million in valuation, growing at a 7.89 % CAGR. A total of USD 526 million was spent on the amyotrophic lateral sclerosis market in 2017.


In addition to sedentary lifestyles, other factors like obesity are driving the growth of the market and increasing the risk of developing ALS. In addition, the growing number of elderly people substantiates market growth, creating a demand for symptomatic and targeted treatments.


However, over the forecast period, ALS treatment may be too expensive to boost the market.


COVID-19 Analysis of Amyotrophic Lateral Sclerosis Market


The ALS Treatment Industry is expected to grow incredibly after the fall due to the Covid19 outbreak. Amid this pandemic, manufacturers are more focused on sustainability and applying key strategies to maintain their status in the industry. amyotrophic lateral sclerosis market players can use the information in this report to handle the impact of this pandemic on the industry.


Amyotrophic Lateral Sclerosis Market Dynamics


As the predominance of amyotrophic parallel sclerosis infection builds, the amyotrophic sidelong sclerosis treatment market is relied upon to develop. A developing number of Americans have amyotrophic sidelong sclerosis, which is analyzed in around 5,000 individuals every year, as per the Centers for Disease Control and Prevention (CDC). Amyotrophic sidelong sclerosis influences 2 to 5 individuals out of each 100,000 individuals across the world. Furthermore, an expanding geriatric populace and a tendency toward an inactive way of life fuel the interest in treatment choices. In like manner, the market should increment in the figure time frame. There are a few factors that will probably block the market during the estimated time frame, including the significant expense of treatment, less mindfulness about ALD, and restricted treatment choices.


Technology Analysis


Headway in innovation and the rising geriatric populace are the main considerations driving the development of the market. Besides, raising extra cash and progression of R&D exercises further improve the general market interest for amyotrophic lateral sclerosis market during the figure time frame 2020-2025. Progression in Technology and expanding mindfulness in the treatment are a few elements driving the market development of this market. Additionally, the FDA likewise endorsed NeuRx Diaphragm Pacing System wherein embedded cathodes and batteries are utilized to contract stomach in the ALS populace which is expanding the market development of amyotrophic horizontal sclerosis.


Amyotrophic Lateral Sclerosis Market Segmental Analysis


There are three types, treatment options, and end-users within the amyotrophic lateral sclerosis market.


Amyotrophic lateral sclerosis market is segmented by type into sporadic and familial. Over the forecast period, the market can be dominated by sporadic ALS, also known as SALS.


The amyotrophic lateral sclerosis market has been segmented based on the type of treatment: medication, physical therapy, respiratory therapy, speech therapy, and others. Among these treatments, medication accounted for the greatest market share in 2017.


End-user segments of the amyotrophic lateral sclerosis market include hospitals, specialty centers, research & academic institutions, and others. Hospitals comprise the largest segment under this heading.


According to the following categories, you can easily understand the global amyotrophic lateral sclerosis market.


Type:



  • Sporadic ALS (SALS)

  • Familial ALS (FALS)


Treatment:



  • Medication

  • Physical Therapy

  • Respiratory Therapy

  • Speech Therapy

  • Others


End-user:



  • Hospitals

  • Specialty Centers

  • Research & Academic Institutes

  • Others


Region:



  • North America


    • US

    • Canada


  • Europe


    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe


  • Asia-Pacific


    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific


  • Rest of the World


    • Middle East

    • Africa

    • Latin America



Amyotrophic Lateral Sclerosis Market Regional Analysis


By Region, the worldwide amyotrophic lateral sclerosis market is sectioned into the Americas, Europe, Asia Pacific, and the Middle East, and Africa.


The Americas is assessed to overwhelm the worldwide amyotrophic lateral sclerosis market attributable to the expanding pool of mindfulness and the rising predominance of hypertension. ALS stays a huge general wellbeing challenge in the US. Consequently, state-run administrations and private non-benefit associations are creating explicit rules for the administration and treatment of ALS. Public and private associations are engaged with key organizations and joint efforts looking for a superior result in the exploration of amyotrophic parallel sclerosis treatment in the area.


The amyotrophic parallel sclerosis market in the European district remains in the second situation as far as the market size predominantly because of the grounded medical care area. A few organizations and exploration foundations are additionally setting up cutting-edge offices to investigate ALS.


Additionally, lately, amyotrophic lateral sclerosis market has been an expansion in the reception of inactive ways of life among individuals. Examination shows that an expansion in proactive tasks, for example, practice helps in diminishing the aggravation and frustrating a portion of the indications, for example, loss of movement in patients who have ALS.


Subsequently, the tendency towards an inactive way of life expands the danger of creating ALS among the older populace, consequently spurring interest for suggestive and designated treatment choices. The improvement of novel restorative methodologies and progressed treatment choices are probably going to push the development of the amyotrophic sidelong sclerosis market during the figure time frame.


While the amyotrophic parallel sclerosis market in the Asia Pacific locale is relied upon to become quickly because of the expanding predominance of the sickness and quickly creating medical care foundation. The expanding economy in the district is assuming an indispensable part in the development of the market. Moreover, the increment in the arrangements of innovative work habitats likewise powers the development of the ALS market in the district.


Competitive Landscape


The amyotrophic lateral sclerosis treatment market is modestly aggressive and comprises a few central parts. A portion of the organizations which are assuming a significant part in the market considered is Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., CORESTEM, Inc, BrainStorm Cell Limited, Amylyx Pharmaceuticals Inc., AB Science, Ionis Pharmaceuticals, Biohaven Pharmaceutical, Biogen, and F.Hoffmann-La Roche AG.


Market players profiled in the amyotrophic parallel sclerosis worldwide amyotrophic lateral sclerosis market report are Sun Pharmaceutical (India), Mitsubishi Tanabe Pharma America (U.S.), Biogen (U.S.), Sanofi (France), Mylan N.V. (U.S.), Covis Pharma (Switzerland), Ionis Pharmaceutical (U.S.), ITF Pharma (U.S.), Ascend Pharmaceuticals LLC (U.S.), Apotex Inc. (Canada), and others.


Recent Developments


A growing number of patients with amyotrophic lateral sclerosis are expected to receive treatment in the future. There are currently only two ALS drugs approved by the FDA: riluzole and edaravone. The FDA has also approved a device that consists of electrodes and batteries that help ALS patients contract their diaphragms. Pain, spasticity, and panic attacks can also be treated by pharmaceuticals. Due to its prevalence across the globe, ALS will result in higher drug demand and growth in this segment.


The overall market also will benefit from several initiatives related to the treatment of amyotrophic lateral sclerosis.


Due to its well-established healthcare infrastructure, increasing healthcare expenditure, and technological advancement, North America currently dominates the Amyotrophic Lateral Sclerosis market in 2019.


Amyotrophic lateral sclerosis is experiencing rapid growth due to advances in technology and an aging population.


In the Amyotrophic Lateral Sclerosis Market report, we will present a detailed analysis of the strengths, weaknesses, and opportunities of prominent players operating in the market.


Treatment costs are expensive, and there are few skilled experts to address these issues.


Report Overview


The Amyotrophic Lateral Sclerosis Treatment market report conveys perpetual data about market definition, arrangements, applications and clarifies the market drivers and impediments from the SWOT examination. The Amyotrophic Lateral Sclerosis Treatment market report has been incorporated through every one of the significant assets and confirms critical insights that are dependable to decide the future possibilities of the Amyotrophic Lateral Sclerosis Treatment industry across the globe. The Amyotrophic Lateral Sclerosis Treatment report conveys astounding information alongside future figures and complete market examination at the worldwide and local levels.



Report Scope:
Report Attribute/Metric Details
  Market Size   2023: USD 841.6 million
  CAGR   2018-2023: 7.89%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment and End-User
  Geographies Covered   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Key Vendors   Sun Pharmaceutical (India), Mitsubishi Tanabe Pharma America (U.S.), Biogen (U.S.), Sanofi (France), Mylan N.V. (U.S.), Covis Pharma (Switzerland), Ionis Pharmaceutical (U.S.), ITF Pharma (U.S.), Ascend Pharmaceuticals LLC (U.S.), Apotex Inc. (Canada)
  Key Market Opportunities   Developing healthcare infrastructure
  Key Market Drivers

  • Rise in the awareness about the disease among patients
  • Rise in the geriatric population


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The treatments included in Amyotrophic Lateral Sclerosis Market are medication, physical therapy, respiratory therapy, speech therapy.

    Various tests included in the ALS Market are Laboratory Tests, Imaging Tests and Others

    Hindering factor of the Amyotrophic Lateral Sclerosis Market would be its high treatment cost.

    Amyotrophic Lateral Sclerosis Market would be led by the hospital segment.

    Valuation of the Amyotrophic Lateral Sclerosis Market would be around USD 841.6 million by 2023.

    Amyotrophic Lateral Sclerosis Market would grow with a CAGR of 7.89% during the forecast period of 2020 to 2027.

    Global Amyotrophic Lateral Sclerosis Treatment Market: Company Landscape


    The Global amyotrophic lateral sclerosis treatment market is dominated by several market players such as Mitsubishi Tanabe Pharma America, Sanofi, Mylan N.V., Covis Pharma, and others. The major players in the amyotrophic lateral sclerosis market are opting for new product launches, strategic collaborations, and partnerships to brace their position in the market.


    Mitsubishi Tanabe Pharma America is one of the leading players in the amyotrophic lateral sclerosis market. The company is a research-driven pharmaceutical company and offers RADICAVA (Edaravone), an intravenous therapy indicated for all adult patients diagnosed with amyotrophic lateral sclerosis (ALS). Radicava is a free radical scavenger and slows the progression of ALS by removing free radicals in the nervous system. The company has successfully integrated small companies through mergers and acquisitions to build a strong supply chain network. High customer satisfaction level, exceptional performance in new markets, and strong brand portfolio add to the company’s competitive advantage.


    Sanofi is a key player owing to its product RILUTEK (Riluzole). RILUTEK is available as a capsule-shaped, film-coated tablet for oral administration containing 50 mg of Riluzole. The drug helps to slow down the worsening of this disease and prolong survival. Rilutek (Riluzole) was the first drug approved by the US Food and Drug Administration (FDA), in December 1995, to treat amyotrophic lateral sclerosis (ALS). It was originally developed by a French company, Rhone-Poulenc Rorer and is now marketed by Sanofi. Sanofi employs a strategy of maintaining the quality of products by maximum automation and rising investments on research and development which help the company in maintaining its market position. Additionally, the company is engaged in strategic collaborations which facilitates it to strengthen its position and expand its market presence globally.


    Covis Pharma is a renowned company in the amyotrophic lateral sclerosis market. The company operates in various business units and produces branded and generic pharmaceutical products and injectables in cardiovascular, central nervous system, oncology, and acute care markets. In April 2015, the company was acquired by Advanz Pharmaceuticals. The strategy of the company is to expand its generic and branded drugs business, thus bracing its position in the market.


    Mylan N.V. accounted is one of the prominent players operating in the global amyotrophic lateral sclerosis treatment market. The company’s global portfolio constitutes more than 7,500 marketed generic and branded generic, brand names, and OTC products around the world covering a wide range of therapeutic areas. The company is engaged in strategic collaborations and mergers which helps the company to hold its market position.


    Sun Pharmaceutical Industries Ltd delivers high quality and reasonable medicines trusted by customers in over 150 countries globally. The company aims to provide high-quality products to expand its generic business, and thus strengthen its position in the market.


    One of the prominent players in the market is ITF Pharma. The company is engaged in the development and sale of branded prescription and non-prescription pharmaceutical products. In September 2018, ITF Pharma announced the FDA approval of tiglutik (Riluzole) oral suspension for the treatment of amyotrophic lateral sclerosis (ALS).


    Other key companies in the amyotrophic lateral sclerosis treatment market are Ascend Pharmaceuticals LLC and Apotex Inc.